Methylprednisolone acetate
| Clinical data | |
|---|---|
| Trade names | Depo-Medrol, Depo-Medrate, Depo-Medrone, others |
| Other names | Depot methylprednisolone acetate; Methylprednisolone 21-acetate; 6α-Methylprednisolone 21-acetate; NSC-48985 |
| Routes of administration | Intramuscular injection |
| Drug class | Corticosteroid; Glucocorticoid |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.000.157 |
| Chemical and physical data | |
| Formula | C24H32O6 |
| Molar mass | 416.514 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Methylprednisolone acetate, sold under the brand names Depo-Medrol among others, is a synthetic glucocorticoid corticosteroid and a corticosteroid ester—specifically the C21 acetate ester of methylprednisolone—which is used in clinical and veterinary medicine. It has been formulated as an aqueous suspension for intramuscular, intra-articular, soft tissue, and intralesional injection alone and in combination with lidocaine, a local anesthetic. Methylprednisolone acetate was previously suspended with polyethylene glycol but is no longer formulated with this excipient due to concerns about possible toxicity. Depo methylprednisolone acetate is a depot injection and is absorbed slowly with a duration of weeks to months with a single intramuscular injection.